New Alzheimer Drug Is A Turning Point In The Fight Against Alzheimer’s Disease, Says Alzheimer’s Drug Trial Patients


New Alzheimer Drug Is A Turning Point Against Alzheimer

Earlier this month, the FDA granted full approval to Lecanemab, also known as Leqembi, new Alzheimer drug in two decades. This groundbreaking drug operates by reducing amyloid plaques in the brain, a characteristic feature of Alzheimer’s disease. 

During the initial clinical trials, two patients shared their personal experiences with Fox News Digital, revealing that Lecanemab demonstrated an impressive 27% slowdown in cognitive decline.

Symptoms Of Alzheimer

Alzheimer’s disease is a neurodegenerative condition that gradually impacts cognitive functions in the brain. As the disease progresses, it causes a decline in memory, thinking abilities, and other mental processes. Symptoms of Alzheimer can vary from person to person, but they generally worsen over time. Some common symptoms include:

  • Memory Loss
  • Confusion and Disorientation
  • Difficulty with problem-solving
  • Changes in mood
  • Lack of self-care

Joan Murtaugh’s New Alzheimer Drug Story

Joan Murtaugh, a 77-year-old resident of Lakewood, Ohio, began experiencing memory issues shortly after her 70th birthday. Recognizing the importance of timely action, her husband, Larry Murtaugh, helped her make an appointment at a brain center clinic. 

Subsequently, in 2017, Joan was diagnosed with mild cognitive impairment. A year later, after undergoing a 3-D MRI and spinal tap, she received the news that she had symptoms Of Alzheimer, which is an enzyme in her spinal fluid indicating a 65% likelihood of developing Alzheimer’s in her lifetime.

In February 2020, Joan received some encouraging news when she became eligible to participate in a double-blind Phase 3 clinical trial for dementia medications called new alzheimer drug Leqembi at the renowned Cleveland Clinic in Ohio.

Read more here: Get Your Eyes Checked Regularly! Study Reveals Link Between Eye Health And Dementia Risk

Among the 1,800 participants worldwide, she was one of only eight individuals chosen to receive the experimental new Alzheimer’s drug at the Cleveland Clinic. Joan believes that her inclusion in the trial was due to the evident presence of plaque in her brain, which was identified as a contributing factor to her Alzheimer’s condition. 

FDA approved new alzheimer drug is a significant sign of hope.

Throughout the trial, Joan describes the drug’s effects as a gradual but noticeable progress, though not a miraculous cure.

Murtaugh shared that throughout the entire trial period, she had not deteriorated; rather, she experienced the same mild symptoms of Alzheimer she had before starting the dementia medications, and there was a possibility that she had even shown some improvement. 

Additionally, she mentioned that despite the known associations of Leqembi with potential side effects, she did not encounter any adverse reactions. According to Murtaugh, the new Alzheimer’s drug represented a source of significant hope for those who all are looking for Alzheimer’s disease medication.

John Domeck’s New Alzheimer Drug Story

John Domeck, a retired attorney from Aurora, Ohio, found himself confronted with an Alzheimer’s diagnosis at the age of 57. His colleagues at the law office and family had noticed Alzheimer’s symptoms like his memory lapsed even before he recognized them himself. 

John had to resort to writing things down to avoid forgetting crucial details, which was a stark contrast to his 30-year history of not needing extensive notes at work.

John shared that over time, his ability to perform work quickly and efficiently declined due to the progression of Alzheimer’s. His wife of 40 years, Ann Domeck, also observed concerning signs at home, but they never anticipated it would be Alzheimer’s disease.

To get a clearer picture of his cognitive health, the Domecks decided to schedule cognitive testing at Cleveland Clinic, which ultimately led to a spinal tap and a confirmed Alzheimer’s diagnosis in July 2019.

A year ago, John’s Alzheimer’s disease medication approach shifted to the “open-label” Leqembi medication, the new dementia medication which he now administers through self-injection at home once a week. 

Ann Domeck expressed that Alzheimer’s had significantly disrupted their lives, but the introduction of the new Alzheimer drug provided a positive impact, somewhat restoring their sense of stability.

Read more here: Alzheimers Drug Gets FDA Approval, Expands Medicare Coverage To Slow Down The Disease

Initially taken aback by the unexpected diagnosis, the Domecks now believe that the dementia medications have granted them the additional time they were informed they might not have had.

Ann Domeck conveyed her gratitude, stating that she thanks God every day for their participation in the trial, as it has been the most beneficial development they have experienced.

Leqembi has received approval specifically for the treatment of individuals with mild cognitive impairment or early-stage Alzheimer’s disease, provided that they have been clinically determined to have amyloid plaques in their brains.

Symptoms of alzheimer

— Share —

— About the Author —

Leave a Reply

Up Next

Beyond Chemical Imbalances: Researchers Shed Light on Social Root Causes Of Depression

In a recent letter to the editor published in Molecular Psychiatry, researchers led by Joanna Moncrieff present a compelling argument challenging the conventional understanding of depression. They assert that rather than being solely attributed to chemical imbalances in the brain, and discuss the social root causes of depression.

According to Moncrieff et al., the evidence for brain differences in depression is lacking, while there is substantial support for the influence of social and environmental factors on mental health.

They argue that the circumstances of life, such as stress and adversity, play a more significant role in shaping depressive symptoms than neuro

Up Next

Study Reveals Presence of Microplastics in Human Brain: Concerns Rise Over Health Implications

In a groundbreaking revelation, researchers from the University of New Mexico have discovered microplastics infiltrating human brain tissue, as reported in a study published in the journal Environment Health Perspectives. The study sheds light on the pervasive presence of microplastics in various organs of the body, including the kidneys, liver, and brain.

Eliseo Castillo, an associate professor leading the research, underscores the widespread distribution of microplastics in the environment, emphasizing their presence in water sources, food items, and even the air we breathe.

Previous studies have estimated that individuals ingest approximately five grams of microplastics weekly, equivalent to the weight of a credit card.

Up Next

Study Reveals Significant Genetic Link Between Treatment-Resistant Depression and Family History

In a groundbreaking study published in the journal JAMA Psychiatry, researchers have uncovered a substantial genetic link between treatment-resistant depression (TRD) and family history.

Led by Dr. Cheng-Ta Li, a professor of medicine at the National Yang-Ming Chiao Tung University in Taipei, Taiwan, the study utilized extensive national health insurance data to investigate the transmission of TRD across generations and its association with other psychiatric disorders.

The findings of the study are particularly significant, as they shed light on the hereditary nature of TRD and its implications for early intervention and treatment.

Up Next

FDA Clears Prescription Digital Therapeutic for Adults with Major Depressive Disorder

The FDA has recently cleared a groundbreaking prescription digital therapeutic, known as Rejoyn, for the treatment of major depressive disorder (MDD) symptoms in adults. This innovative therapy, developed by Otsuka Pharmaceutical Co. Ltd. in collaboration with Click Therapeutics Inc., aims to provide adjunctive care for individuals who have been prescribed antidepressants as part of clinician-managed outpatient treatment.

Rejoyn is a 6-week treatment program designed to assist individuals aged 22 years and older in regulating their emotions through a combination of clinically validated cognitive training exercises and therapeutic lessons.

The therapy utilizes digital platforms to deliver pe

Up Next

Sweet Science: How Chocolate’s Theobromine May Aid Weight Loss and Alzheimer’s Prevention

A recent study conducted by researchers at Zhengzhou University in China suggests that indulging in chocolate could offer various health benefits, including weight loss assistance and Alzheimer’s prevention.

Published in the Journal of Functional Foods, the study highlights the potential of a chemical compound found in chocolate called theobromine to positively impact both the body and the brain.

Theobromine, present in cocoa beans, boasts anti-inflammatory properties and is rich in antioxidants, making it beneficial for brain health. According to scientists, this compound can protect against Alzhei

Up Next

New Study Finds High Genetic Risk for Obesity May Require Over 14,500 Daily Steps

A recent study published in JAMA Network Open reveals a significant association between genetic risk for obesity and the amount of physical activity required to mitigate the risk.

Led by Dr. Evan Brittain, associate professor of medicine at Vanderbilt University Medical Center, the study analyzed data from 3,124 participants in the National Institutes of Health’s All of Us Research Program to explore the link between genetic predisposition to obesity and recommended step counts for reducing the genetic risk of developing the condition.

Findings from the study indicate that individuals with a higher genetic risk of obesity may need to undertake more physical activity

Up Next

Ketogenic Diets Show Promise for Bipolar Disorder and Schizophrenia Treatment, Stanford Study Finds

A recent study led by researchers at Stanford University suggests that ketogenic diets may offer benefits for individuals with bipolar disorder and schizophrenia, shedding light on the potential role of diet in managing serious mental illnesses.

The findings, published in Psychiatry Research, highlight the positive impact of a ketogenic regime on both psychiatric outcomes and metabolic syndromes commonly associated with these conditions.

Unlike traditional diets, ketogenic diets are characterized by high fat, moderate protein, and very low carbohydrate intake. The study, led by Dr. Shebani Sethi, a clinical ass